This hypothesis is further supported by the observation that four of the six TET2/ASXL1 co-mutated patients exhibited excess marrow blasts approaching 20% and/or suggestive multilineage dysplasia in the months immediately preceding AML diagnosis. The gene discussed is ASXL1; the disease is acute myeloid leukemia.